Novo Nordisk’s Liraglutide Adds Thyroid Cancer Risk To The Diabetes Safety Gauntlet
This article was originally published in The Pink Sheet Daily
Executive Summary
In addition to weighing prior data against new cardiovascular outcomes standards, FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will assess April 2 whether a cancer risk in rodents translates to humans.
You may also be interested in...
Survivor: Novo Nordisk Sets Levemir Apart Amid Synthetic Insulin Scare
There will be winners and losers for the makers of type 2 diabetes drugs as doctors and patients absorb news of a potentially higher cancer risk for Sanofi-Aventis' long-acting insulin Lantus. Not surprisingly, Novo Nordisk is working hard to come out on top in any shakeout and held a recent presentation to make its case to investors
Survivor: Novo Nordisk Sets Levemir Apart Amid Synthetic Insulin Scare
There will be winners and losers for the makers of type 2 diabetes drugs as doctors and patients absorb news of a potentially higher cancer risk for Sanofi-Aventis' long-acting insulin Lantus. Not surprisingly, Novo Nordisk is working hard to come out on top in any shakeout and held a recent presentation to make its case to investors
Bristol/AZ Saxagliptin Safety Review: All Signs Point to Positive Committee Outcome
Upcoming FDA advisory committee review of DPP4 inhibitor poses first test of new diabetes cardiovascular safety guidelines. Bristol and AstraZeneca won’t be the only companies watching carefully.